$AMGN , the second-largest holding in $SCHD, delivered a strong Q2. ✅ EPS: $6.29 (beat by $0.67) ✅ Revenue: $10.1B (+10% YoY, beat by $680M) Key highlights: 🟢 Product sales increased 9%, driven by higher volumes. 🟢 22 products posted double-digit sales growth. 🟢 17 products are now generating annual sales above $1B. Updated 2026 Outlook 📈 Revenue: $38.2B–$39.4B, ahead of the ~$37.7B consensus. 📈 Non-GAAP EPS: $22.30–$23.50. 💰 Up to $3.0B in share repurchases. Shares initially rallied after the earnings release before giving back most of those gains in after-hours trading. Overall, another solid quarter from one of $SCHD’s largest holdings.
1,282 views
1 Comments
Scott S@scottsinvesting · 20d
Thanks for sharing Cooper... I own $AMGN and $SCHD for that matter and honestly forgot Amgen was having earnings today. I've owned it for a very long time now and admittedly don't pay nearly as close attention to it as I should considering how much I own.
See the full comment section 👀Sign up for the full Blossom experience!
